Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Timing is crucial for HSV-1 thymidine kinase/ganciclovir-mediated cytotoxicity
April 22nd, 2003
Timing is crucial for HSV-1 thymidine kinase/ganciclovir-mediated cytotoxicity. "Cancer gene therapy with the aid of herpes simplex virus type I thymidine kinase gene (HSV-TK) and anti-herpes drug ganciclovir (GCV) has been widely used and its efficacy has been demonstrated in a variety of different malignant cells and animal tumor models. It is also commonly accepted, however, that this gene therapy regimen needs to be enhanced for a true clinical success," investigators in Finland report. "We studied whether polyamine biosynthesis inhibition by 2-difluoromethylornithine (DFMO), a clinically tested and well-tolerated chemotherapeutic drug, can...
Source: Cancer Weekly (2003-04-22)
|
